2013 Awarded Grant

John Carter Ralphe, MD

Human iPS Cells and ECT in the Study of Hypertrophic Cardiomyopathy
University of Wisconsin, Madison, WI
2013 Amount Awarded – $50,000

One of the most common genetic causes of hypertrophic cardiomyopathy (HCM) involves defects in a protein called cardiac myosin binding protein C (cMyBP-C). This protein makes up part of the contractile unit within each cell of the heart muscle and participates in the regulation of muscle contraction. Exactly how some of mutations in the DNA that produces cMyBP-C lead to severe, early childhood-onset HCM is unclear. The proposed research will examine the impact of an identified HCM-causing mutation in human cells using skin fibroblasts that have been genetically reprogrammed through induced pluripotent stem cells (iPS cells) to become beating heart cells. The HCM mutation within these cells will be expressed and examined in how it affects the way the cells contract, and importantly, how the cells become dysfunctional on their way to developing hypertrophy. For the study, iPS-derived heart cells will be formed into a three-dimensional strip of muscle referred to as human engineered cardiac tissue (hECT). Using this human heart muscle test system, the study will seek to identify how environmental factors may modify, either positively or negatively, the progression of the disease. These studies will enhance our understanding of the genetic forms of HCM and provide insight into the development of more effective treatments.

Stay Informed
Keep current on PCM research and CCF happenings in our Heart to Heart newsletter.
Unite and Fight
Connect with hundreds of other families struggling with this disease through our online member community.
Shop for a Cure
Shop for CCF merchandise to support our research and education efforts.
The Children's Cardiomyopathy Foundation is a 501 (c)(3) non-profit recognized by the U.S. Internal Revenue Service.
© 2020 Children's Cardiomyopathy Foundation. All rights reserved.